← Back to Analyst Consensus 
EBS Buy
Emergent BioSolutions Inc.
Current Price —
Implied Upside —
Analysts 7
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 2, 2026 (7 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 9, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Dec 16, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Sep 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Apr 1, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Mar 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Mar 4, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Jan 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Jan 10, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Dec 30, 2024 | HC Wainwright & Co. | initiate | — → Buy | $15 | 44% |
| Nov 7, 2024 | Benchmark | maintain | Buy → Buy | $12 | 54% |
| Sep 13, 2024 | Rodman & Renshaw | reiterate | Buy → Buy | $16 | 40% |
| Aug 22, 2024 | Rodman & Renshaw | initiate | — → Buy | $16 | 40% |
| Aug 16, 2024 | Benchmark | reiterate | Buy → Buy | $8 | 54% |
| Aug 9, 2024 | Benchmark | reiterate | Buy → Buy | $8 | 54% |
| Jul 3, 2024 | Benchmark | reiterate | Buy → Buy | $8 | 54% |
| Jul 2, 2024 | Benchmark | reiterate | Buy → Buy | $8 | 54% |
| Jun 24, 2024 | Benchmark | reiterate | Buy → Buy | $8 | 54% |
| Jun 21, 2024 | Benchmark | reiterate | Buy → Buy | $8 | 54% |
| Jun 20, 2024 | Benchmark | maintain | Buy → Buy | $8 | 54% |
| Apr 11, 2024 | Benchmark | reiterate | Buy → Buy | $5 | 54% |
| Mar 7, 2024 | Benchmark | upgrade | Hold → Buy | $5 | 54% |
| Aug 29, 2023 | Benchmark | downgrade | Buy → Hold | $0 | 54% |
| May 31, 2023 | Benchmark | reiterate | Buy → Buy | $22 | 54% |
| May 19, 2023 | Benchmark | reiterate | Buy → Buy | $22 | 54% |
| Apr 10, 2023 | Benchmark | upgrade | Hold → Buy | $22 | 54% |
| Mar 17, 2023 | JP Morgan | downgrade | Neutral → Underweight | $9 | 55% |
| Nov 10, 2022 | Benchmark | downgrade | Buy → Hold | $0 | 54% |
| Nov 9, 2022 | Chardan Capital | maintain | — → Buy | $55 | 47% |
| Sep 12, 2022 | Cowen & Co. | maintain | — → Market Perform | $29 | — |
| May 4, 2022 | Wells Fargo | maintain | — → Equal-Weight | $38 | 54% |
| Apr 29, 2022 | Chardan Capital | maintain | — → Buy | $65 | 47% |
| Mar 10, 2022 | Wells Fargo | maintain | — → Equal-Weight | $40 | 54% |
| Nov 10, 2021 | Chardan Capital | maintain | — → Buy | $75 | 47% |
| Nov 8, 2021 | Benchmark | downgrade | Buy → Hold | $0 | 54% |
| May 5, 2021 | Argus Research | downgrade | Buy → Hold | $0 | 54% |
| Apr 30, 2021 | Chardan Capital | maintain | — → Buy | $92 | 47% |
| Apr 7, 2021 | Benchmark | initiate | — → Buy | $150 | 54% |
| Feb 24, 2021 | Chardan Capital | upgrade | Neutral → Buy | $112 | 47% |
| Feb 19, 2021 | Chardan Capital | downgrade | Buy → Neutral | $112 | 47% |
| Jan 8, 2021 | Wells Fargo | downgrade | Overweight → Equal-Weight | $0 | 54% |
| Jul 31, 2020 | Chardan Capital | maintain | — → Buy | $112 | 47% |
| Jul 17, 2020 | Cantor Fitzgerald | maintain | — → Overweight | $110 | 50% |
| Jun 8, 2020 | Cantor Fitzgerald | maintain | — → Overweight | $85 | 50% |
| May 6, 2020 | Argus Research | maintain | — → Buy | $90 | 54% |
| May 1, 2020 | Cantor Fitzgerald | maintain | — → Overweight | $86 | 50% |
| May 1, 2020 | Chardan Capital | maintain | — → Buy | $86 | 47% |
| Apr 30, 2020 | Wells Fargo | maintain | — → Overweight | $85 | 54% |
| Feb 25, 2020 | Wells Fargo | maintain | — → Overweight | $75 | 54% |
Price Target Trend
Apr 29, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
+1y —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days